648 results match your criteria: "Small Cell Carcinoma of the Prostate"
Genetic variants of , , and in the T cell exhaustion-related genes are associated with non-small cell lung cancer survival.
Front Immunol
October 2024
Duke Cancer Institute, Duke University Medical Center, Durham, NC, United States.
Article Synopsis
- T cell exhaustion is linked to decreased effectiveness of immune checkpoint inhibitors in lung cancer, which has the highest mortality rate among cancers, although the genetic variants related to T cell exhaustion in non-small cell lung cancer (NSCLC) prognosis are not well studied.!* -
- A two-stage analysis using existing genome-wide association study (GWAS) datasets identified 1,721 single nucleotide polymorphisms (SNPs) related to T cell exhaustion that were associated with overall survival in NSCLC patients, with 125 confirmed significant after further validation.!* -
- Three specific SNPs (rs10493829, rs2239193, and rs3136651) showed a significant association with overall survival, highlighting that certain genotypes
Oral Microbiome and Subsequent Risk of Head and Neck Squamous Cell Cancer.
JAMA Oncol
November 2024
Department of Population Health, NYU Grossman School of Medicine, New York, New York.
Article Synopsis
- The study investigates the link between oral microbiota (bacteria and fungi) and the risk of developing head and neck squamous cell cancer (HNSCC), focusing on prospective data rather than past studies.
- Conducted among participants from three large cohorts, 236 HNSCC cases were compared to 485 controls matched on various demographic factors over an average follow-up of 5.1 years.
- While overall microbiome diversity did not correlate with HNSCC risk, the researchers identified 13 specific oral bacterial species that significantly differed between the cases and controls, suggesting a potential biological marker for cancer risk.
Potentially functional variants of PARK7 and DDR2 in ferroptosis-related genes predict survival of non-small cell lung cancer patients.
Int J Cancer
February 2025
Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA.
Ferroptosis, a form of regulated cell death, is characterized by iron-dependent lipid peroxidation. It is recognized increasingly for its pivotal role in both cancer development and the response to cancer treatments. We assessed associations between 370,027 single-nucleotide polymorphisms (SNPs) within 467 ferroptosis-related genes and survival of non-small cell lung cancer (NSCLC) patients.
View Article and Find Full Text PDFThe Use of Lurbinectedin for the Treatment of Small Cell and Neuroendocrine Carcinoma of the Prostate.
Clin Genitourin Cancer
October 2024
Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA; Department of Medical Oncology and Developmental Therapeutics, City of Hope Cancer Center, Goodyear, AZ, USA. Electronic address:
Article Synopsis
- Lurbinectedin is FDA-approved for treating metastatic small cell lung cancer (SCLC), but there is no data on its use for small cell or neuroendocrine prostate cancer (SC/NEPC), which behaves similarly.
- A study involving 18 SC/NEPC patients treated with lurbinectedin reported a clinical benefit rate of 56%, with common treatment-related adverse events including fatigue and anemia.
- Results showed modest clinical benefits: median overall survival was about 6 months and progression-free survival was around 3.35 months, highlighting the need for further studies to confirm lurbinectedin's effectiveness as a treatment option for SC/NEPC.
Potentially functional variants of in immunity B cell-related genes are associated with non-small cell lung cancer survival.
Front Immunol
August 2024
Duke Cancer Institute, Duke University Medical Center, Durham, NC, United States.
Article Synopsis
- B cells are important in cancer progression, particularly non-small cell lung cancer (NSCLC), but the impact of genetic variants in immunity-related genes on patient survival is unclear.
- The study analyzed over 10,000 genetic variants in B cell-related genes among nearly 1,200 NSCLC patients and identified 369 single nucleotide polymorphisms (SNPs) linked to overall survival, further validating 18 SNPs in an additional patient group.
- Two specific SNPs were found to significantly influence patient survival, with certain unfavorable combinations of these genotypes leading to poorer outcomes, and gene expression analyses indicated that specific alleles correlate with higher gene activity in lung tissues.
Extracellular vesicles carry transcriptional 'dark matter' revealing tissue-specific information.
J Extracell Vesicles
August 2024
Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, USA.
Article Synopsis
- All cells, regardless of being eukaryotic or prokaryotic, release extracellular vesicles (EVs) for various functions like communication and waste disposal, with small EVs containing small RNAs that may serve as important disease markers.
- This study focuses on identifying unannotated small RNAs in EVs from prostate cancer and benign tissues, overcoming limitations of previous sequencing methods to explore the 'dark matter' of genomes and their role in gene expression regulation.
- Researchers found that these novel EV-associated small RNAs, termed EV-UGRs, showed a significant reduction in aggressive prostate cancer, but their expression increased after treatment, potentially promising for fluid-based diagnostics in cancer screening.
Prostate Type Malignancies Arising in Ovarian Teratomas - A Report of Two Patients.
Int J Surg Pathol
August 2024
Departments of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Article Synopsis
- The identification of benign prostatic tissue in mature teratomas of the ovary and testis is rare, with only a few documented cases and even fewer involving prostatic-type adenocarcinoma.
- The article presents two cases of tumors in ovarian mature teratomas that included prostatic-type carcinoma, one with infiltrative atypical glands and another with low-grade basal cell carcinoma alongside adenocarcinoma of the prostate.
- Both patients showed no signs of recurrence during follow-up, and the authors emphasize the importance of studying similar cases to improve understanding of their prognosis and management.
Potentially functional variants of ERRFI1 in hypoxia-related genes predict survival of non-small cell lung cancer patients.
Cancer Med
August 2024
Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA.
Article Synopsis
- Hypoxia plays a significant role in cancer aggression, impacting processes like blood vessel formation and immune response, yet the influence of genetic variants in hypoxia-related genes on survival in non-small cell lung cancer (NSCLC) remains unclear.
- Researchers studied 16,092 single-nucleotide polymorphisms (SNPs) in 182 hypoxia-related genes among NSCLC patients, using data from two cancer studies to identify any survival associations.
- They found that the ERRFI1 gene variant rs28624 was linked to lower overall survival rates in patients, indicating that certain genetic variations could affect how long individuals with NSCLC live, possibly by influencing gene expression.
Immunotherapy for small cell carcinoma of the prostate: A new treatment frontier.
Asian J Surg
July 2024
Department of Radiation Oncology, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China. Electronic address:
[Diagnosis and treatment of small-cell carcinoma of the prostate: A report of 2 cases].
Zhonghua Nan Ke Xue
January 2024
Department of Urology, General Hospital of Eastern Theater Command, Nanjing / Jinling Hospital Affiliated to Nanjing University School of Medicine, Nanjing, Jiangsu 210002, China.
Article Synopsis
- This study examines small-cell carcinoma of the prostate (SCCP), focusing on its symptoms, diagnosis, and treatment options based on two retrospective cases between 2017 and 2018.
- Both patients experienced severe urinary issues and showed elevated PSA levels; one underwent a biopsy and the other a laser procedure, revealing SCCP alongside prostate adenocarcinoma.
- The prognosis for SCCP is poor, with an average survival of 7 to 10 months post-diagnosis; treatments are limited, primarily involving chemotherapy inspired by small-cell lung cancer therapies, though effective management remains elusive.
Small Cell Carcinoma Prostate: A Case Report with Findings on 18-F FDG PET/CT.
Indian J Nucl Med
May 2024
Department of Medical Oncology, National Cancer Institute (NCI-AIIIMS), Jhajjar, Haryana, India.
Article Synopsis
- Small-cell carcinoma of the prostate (SCCP) is a rare and aggressive cancer that forms differently than standard prostate cancer, leading to a worse overall prognosis.
- Approximately 50% of patients diagnosed with SCCP have cancer that has already spread (metastasized) when they first seek treatment.
- A case study highlights the unique detection of SCCP using 18-F fluorodeoxyglucose PET/CT, detailing an unusual finding in the left internal mammary lymph node.
Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapies.
Proc Natl Acad Sci U S A
July 2024
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Article Synopsis
- Targeting cell surface molecules with therapies like radioligands and antibodies has been effective in treating various cancers, but the impact of lineage plasticity on these markers is still poorly understood.
- A specific example of lineage plasticity is the transformation of prostate adenocarcinoma to neuroendocrine prostate cancer, which poses significant treatment challenges and worsens patient survival rates.
- Research using advanced single-cell analyses and large tumor sample studies revealed significant phenotypic variability and shared gene-regulatory networks between NEPC and small cell lung cancer, raising concerns about the effectiveness of current therapies while suggesting potential for better patient selection in clinical trials.
Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk.
Int J Cancer
October 2024
Department of Biology, University of Pisa, Pisa, Italy.
Article Synopsis
- CoRSIVs are regions in the genome with consistent DNA methylation patterns across tissues but show individual differences and are influenced by nearby genetic variants.
- This study focused on investigating SNPs within CoRSIVs and their potential link to pancreatic ductal adenocarcinoma (PDAC) risk, analyzing data from over 14,000 patients and 247,000 controls.
- The research identified that the A allele of SNP rs2976395 is linked to a higher risk of PDAC in Europeans and is associated with changes in DNA methylation and overexpression of the prostate stem cell antigen gene, highlighting the need for further functional studies.
Prognostic nomogram to predict cancer-specific survival with small-cell carcinoma of the prostate: a multi-institutional study.
Front Oncol
May 2024
Department of Radiation Oncology, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Article Synopsis
- The study focuses on identifying factors that predict cancer-specific survival (CSS) in patients with Small-Cell Carcinoma of the Prostate (SCCP) and aims to create a prognostic model for better prediction of survival outcomes.
- Using data from the SEER database, researchers utilized Kaplan-Meier survival analysis and regression models, determining significant factors like age, race, and chemotherapy, resulting in 12-month and 24-month CSS rates of 44.6% and 25.5% respectively.
- The developed nomogram showed strong predictive performance, surpassing the traditional AJCC staging system for CSS predictions at both 12 and 24 months, indicating its potential usefulness in clinical
A hospital-based study of prostate biopsy results in Indian males.
J Family Med Prim Care
March 2024
Department of Pathology, Mahavir Institute of Medical Sciences, Vikarabad, Telangana, India.
Article Synopsis
- The study investigates prostate diseases by examining biopsy specimens from patients showing symptoms of prostate issues, highlighting the importance of early diagnosis through histopathological testing.
- Conducted at Deccan College of Medical Sciences from June 2012 to September 2014, the study analyzed 300 prostate biopsy specimens, assessing various histological features to identify different prostate conditions.
- The results showed that out of the biopsies, 18.66% were inflammatory lesions, 32.66% were benign prostatic hyperplasia (BPH), 37.33% were BPH with premalignant changes, and 11.33% were malignant tumors, with chronic prostatitis being the most common inflammatory issue observed.
Adherence to the low-fat diet pattern reduces the risk of lung cancer in American adults aged 55 years and above: a prospective cohort study.
J Nutr Health Aging
July 2024
Health Medicine Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. Electronic address:
Article Synopsis
- - A study was conducted to explore the relationship between low-fat dietary patterns and lung cancer risk in adults aged 55 and older, using data from over 98,000 participants in the PLCO Cancer Screening Trial who had no prior cancer history.
- - Researchers assessed participants' diets with a food frequency questionnaire and calculated a low-fat diet score to analyze the impact of different types of fat on lung cancer incidence over an average follow-up of 8.8 years.
- - The findings revealed that individuals with higher adherence to a low-fat diet had a lower risk of developing lung cancer, particularly non-small cell lung cancer, compared to those with lower adherence.
Paraneoplastic syndrome as a manifestation small cell carcinoma of the prostate: a rare presentation within a rare tumor.
Intern Emerg Med
August 2024
Istanbul Medical Faculty, Department of Internal Medicine, Istanbul University, Istanbul, Turkey.
Small Cell Neuroendocrine Carcinoma of the Prostate on 18 F-DCFPyL and 18 F-FDG PET/CT.
Clin Nucl Med
April 2024
IMED Radiology Network, Miranda.
Article Synopsis
- A 51-year-old man was diagnosed with small cell neuroendocrine carcinoma of the prostate and underwent staging with 18 F-DCFPyL PET/CT, revealing a single metastasis in his left acetabulum.
- A follow-up 18 F-FDG PET/CT scan showed high activity in the prostate and widespread cancer spread to pelvic and thoracic lymph nodes, along with the previously identified acetabular metastatic site.
- Despite an initial positive response to treatment, an 8-month follow-up PET scan indicated significant worsening of nodal disease and the emergence of additional metastases.
Experience and Lessons Learned in the Treatment of Transforming Small Cell Neuroendocrine Carcinoma of the Prostate: A Case Report and Literature Review.
Case Rep Oncol
February 2024
Department of Oncology, Affiliated Hospital of Southwest Medical University, Luzhou, China.
Article Synopsis
- Small cell neuroendocrine carcinoma of the prostate (SCNECP) is a rare, aggressive cancer type that often develops from conventional prostate adenocarcinoma (CPAC), typically diagnosed at advanced stages with metastasis to organs like the liver and lungs.
- * A case study of a 73-year-old man reveals that despite initial treatment leading to a decrease in prostate-specific antigen (PSA) levels, other tumor markers began to rise, indicating potential transformation to SCNECP.
- * The findings suggest that monitoring tumor markers beyond just PSA is crucial for early detection of SCNECP, as a rise in markers like CEA, CA199, and CA125 may signal an important change in the disease's progression.*
Long-Term Survival After Definitive Concurrent Chemoradiation Therapy for Synchronous Small Cell Neuroendocrine Carcinoma of the Urinary Bladder and Adenocarcinoma of the Prostate: A Case Report.
Cureus
January 2024
Radiation Oncology, Coffs Harbour Health Campus, Mid North Coast Local Health District, New South Wales, AUS.
Article Synopsis
- The text discusses the traditional treatment approach for synchronous prostate and bladder cancers, which typically involves radical cystoprostatectomy and may include chemotherapy, but notes a lack of reports on curative chemoradiation therapy.
- It presents a unique case of a 70-year-old man with both small cell and urothelial carcinoma in the bladder and adenocarcinoma in the prostate, who achieved long-term survival after receiving concurrent chemoradiotherapy.
- The case suggests that definitive chemoradiation therapy is a viable and effective option for organ preservation in patients with localized synchronous prostate and bladder cancers, with minimal side effects.
Carboplatin and Etoposide for the Treatment of Metastatic Prostate Cancer with or without Neuroendocrine Features: A French Single-Center Experience.
Cancers (Basel)
January 2024
Department of Medical Oncology, Georges-François Leclerc Cancer Center, 21000 Dijon, France.
Article Synopsis
- Chemotherapy with carboplatin and etoposide (CE) is often used for metastatic prostate cancer, but the actual benefits are not well documented in recent studies.
- A study analyzed the effects of CE on 69 patients, showing limited efficacy, especially in heavily pretreated adenocarcinoma patients, with a PSA response in only 15.8% of cases and differing survival rates based on neuroendocrine marker status.
- The findings suggest that combining different types of metastatic prostate cancer for treatment evaluation may not be appropriate, as CE chemotherapy appears to have a poor risk-benefit balance, marked by high toxicity and low response rates in heavily treated patients.
Emerging Insights in Small-Cell Carcinoma of the Genitourinary Tract: From Diagnosis to Novel Therapeutic Horizons.
Am Soc Clin Oncol Educ Book
January 2024
University Hospitals Seidman Cancer Center, Cleveland, OH.
Article Synopsis
- Small-cell carcinomas (SCCs) in the genitourinary tract are rare but aggressive cancers primarily found in the bladder and prostate, often presenting with severe urinary symptoms and metastases.
- Treatment typically involves a combination of platinum-based chemotherapy, surgery, and radiation, especially for bladder SCC which frequently shows nodal and metastatic spread.
- Current research is focused on understanding the genetic factors behind the development of these cancers and is leading to ongoing clinical trials for new therapies.
Diagnosis and management of neuroendocrine prostate cancer.
Prostate
April 2024
Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.
Article Synopsis
- Prostate cancer (PC) often progresses to a more aggressive form called treatment-emergent neuroendocrine PC (t-NEPC), which is resistant to standard androgen receptor therapies and has a poor prognosis.
- Current literature suggests that t-NEPC may respond better to platinum-based chemotherapy, but there is still a lack of defined treatment strategies and limited prospective clinical trial data.
- Advances in genomic and molecular classification of NEPC, along with the development of new biomarkers, could improve early diagnosis and help identify effective treatments for this challenging form of cancer.
Review of the Developing Landscape of Prostate Biopsy and Its Roles in Prostate Cancer Diagnosis and Treatment.
Arch Esp Urol
November 2023
Department of Pathology, Kanagawa Cancer Center, 241-8515 Yokohama, Japan.
Article Synopsis
- Prostate cancer is a major global health issue, with the Gleason score (GS) and Grade Group (GG) still vital for grading malignancy, even as biopsy procedures evolve.
- Recent advancements in imaging, particularly magnetic resonance imaging, have improved the accuracy and efficiency of biopsies, enhancing diagnosis.
- Understanding different cancer patterns, like cribriform and intraductal carcinoma, as well as the distinctions between various types of prostate cancer, is critical for effective treatment, especially with the rise of genomic insights in precision medicine.